Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official Title: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
In Brief: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Description: Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.
Ages Eligible: 12 Years and older
Start Date: October 3, 2019
Completion Date (estimated): November 30, 2021
Status: Active, recruiting
Study ID from ClinicalTrials.gov: NCT04057573
Other Study ID Numbers: INCB 18424-307
- Center For Dermatology and Plastic Surgery: Scottsdale, Arizona, United States, 85260
- Burke Pharmaceutical Research: Hot Springs, Arkansas, United States, 71913
- Marvel Clinical Research: Huntington Beach, California, United States, 92647
- Rady Children's Hospital: San Diego, California, United States, 92123
- Clinical Research Center of Connecticut: Danbury, Connecticut, United States, 06810
- Harmony Medical Research Institute: Hialeah, Florida, United States, 33016
- San Marcus Research Clinic: Miami Lakes, Florida, United States, 33014
- ForCare Medical Center: Tampa, Florida, United States, 33613
- Metabolic Research Institute: West Palm Beach, Florida, United States, 33401
- Northwestern University, Chicago, Illinois, United States, 60611
- Great Lakes Research Group: Bay City, Michigan, United States, 48706
- Washington University in St Louis: Saint Louis, Missouri, United States, 63141
- SUNY Downstate Medical Center: Brooklyn, New York, United States, 11203
- Forest Hills Dermatology Group: Forest Hills, New York, United States, 11375
- Buka Dermatology: New York, New York, United States, 10012
- M3 Wake Research: Raleigh, North Carolina, United States, 27612
- Wake Forest University Health Sciences: Winston-Salem, North Carolina, United States, 27157
- KGL Skin Study Center: Broomall, Pennsylvania, United States, 19008
- Dermatology Associates of Plymouth Meeting: PC Plymouth Meeting, Pennsylvania, United States, 19462
- Palmetto Clinical Trial Services: Anderson, South Carolina, United States, 29621
- International Clinical Research-Tennessee: Murfreesboro, Tennessee, United States, 37130
- Progressive Clinical Research - San Antonio: San Antonio, Texas, United States, 78213
- Dermatology Clinical Research Center of San Antonio; San Antonio, Texas, United States, 78229
- Dermatology Specialists of Spokane: Spokane, Washington, United States, 99202
Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email email@example.com. Please refer to this study by its NCT number.
- Will it spread?
Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...
- I have vitiligo: will my children have vitiligo, too?
Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.